An update on biomarkers of heart failure in hypertensive patients

被引:54
作者
Gluba, Anna [2 ]
Bielecka, Agata [1 ]
Mikhailidis, Dimitri P. [3 ]
Wong, Nathan D. [4 ]
Franklin, Stanley S. [4 ]
Rysz, Jacek [2 ]
Banach, Maciej [1 ]
机构
[1] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Hypertens, Lodz, Poland
[2] Med Univ Lodz, Dept Nephrol Hypertens & Family Med, Lodz, Poland
[3] UCL, Sch Med, Dept Clin Biochem, London W1N 8AA, England
[4] Univ CA, Dept Med, Irvine, CA USA
关键词
biomarkers; blood pressure; diagnosis; heart failure; hypertension; LEFT-VENTRICULAR MASS; SERUM URIC-ACID; BRAIN NATRIURETIC PEPTIDE; CARDIAC MYOCYTE HYPERTROPHY; ACUTE MYOCARDIAL-INFARCTION; PLASMA CARDIOTROPHIN-1; DIASTOLIC DYSFUNCTION; ADULT CARDIOMYOCYTES; CARBOHYDRATE ANTIGEN-125; CARDIOVASCULAR EVENTS;
D O I
10.1097/HJH.0b013e3283569a9c
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Biomarkers should have high sensitivity, specificity, reproducibility, be cost-effective, and provide incremental predictive or diagnostic utility over standard risk factors or tests. Despite numerous studies investigating biomarkers in heart failure (HF), there are only a few that predict HF in hypertensive patients. This article summarizes data from numerous studies concerning possible biomarkers of HF in hypertensive patients such as: serum uric acid (SUA), interleukins, monocyte chemoattractant protein one (MCP-1), cardiotrophin-1 (CT-1), carboxy-terminal propeptide of procollagen type I (PICP), type I collagen telopeptide (CITP) and N-terminal propeptide of type III procollagen (PIIINP), metalloproteinases (MMPs), B-type natriuretic peptide (BNP) and its derivatives, glycoprotein CA125 and cystatin C. Early detection of patients of increased risk of hypertensive heart disease may result in early implementation of effective preventive strategies. Therefore, there is need to identify newer biomarkers, if they can improve risk prediction, identifying patients, in which earlier or more aggressive intervention will improve clinical outcomes.
引用
收藏
页码:1681 / 1689
页数:9
相关论文
共 109 条
[1]   Matrix metalloproteinases/tissue inhibitors of metalloproteinases - Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease [J].
Ahmed, SH ;
Clark, LL ;
Pennington, WR ;
Webb, CS ;
Bonnema, DD ;
Leonardi, AH ;
McClure, CD ;
Spinale, FG ;
Zile, MR .
CIRCULATION, 2006, 113 (17) :2089-2096
[2]   Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults [J].
Alagiakrishnan, Kannayiram ;
Banach, Maciej ;
Jones, Linda G. ;
Datta, Subrata ;
Ahmed, Ali ;
Aronow, Wilbert S. .
ANNALS OF MEDICINE, 2013, 45 (01) :37-50
[3]   Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure [J].
Alcaino, Hernan ;
Greig, Douglas ;
Chiong, Mario ;
Verdejo, Hugo ;
Miranda, Rodrigo ;
Concepcion, Roberto ;
Vukasovic, Jose Luis ;
Diaz-Araya, Guillermo ;
Mellado, Rosemarie ;
Garcia, Lorena ;
Salas, Daniela ;
Gonzalez, Leticia ;
Godoy, Ivan ;
Castro, Pablo ;
Lavandero, Sergio .
EUROPEAN JOURNAL OF HEART FAILURE, 2008, 10 (07) :646-651
[4]   Metabolic, functional, and haemodynamic staging for CHF? [J].
Anker, SD ;
Coats, AJS .
LANCET, 1996, 348 (9041) :1530-1531
[5]   Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging [J].
Anker, SD ;
Doehner, W ;
Rauchhaus, M ;
Sharma, R ;
Francis, D ;
Knosalla, C ;
Davos, CH ;
Cicoira, M ;
Shamim, W ;
Kemp, M ;
Segal, R ;
Osterziel, KJ ;
Leyva, F ;
Hetzer, R ;
Ponikowski, P ;
Coats, AJS .
CIRCULATION, 2003, 107 (15) :1991-1997
[6]   Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study [J].
Athyros, Vassilios G. ;
Karagiannis, Asterios ;
Ganotakis, Emmanouel S. ;
Paletas, Konstantinos ;
Nicolaou, Vassilios ;
Bacharoudis, George ;
Tziomalos, Konstantinos ;
Alexandrides, Theodore ;
Liberopoulos, Evangelos N. ;
Mikhailidis, Dimitri P. .
CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (08) :1659-1668
[7]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[8]   RENIN-ANGIOTENSIN SYSTEM INVOLVEMENT IN PRESSURE-OVERLOAD CARDIAC-HYPERTROPHY IN RATS [J].
BAKER, KM ;
CHERNIN, MI ;
WIXSON, SK ;
ACETO, JF .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 259 (02) :H324-H332
[9]  
Bakhtiar Ray, 2008, Journal of Pharmacological and Toxicological Methods, V57, P85, DOI 10.1016/j.vascn.2007.10.002
[10]   Should we have any doubts about hypertension therapy in elderly patients? ACCF/AHA 2011 expert consensus document on hypertension in the elderly [J].
Banach, Maciej ;
Aronow, Wilbert S. .
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2011, 121 (7-8) :253-258